These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 11508790)
1. P53 mutations in thyroid carcinoma: tidings from an old foe. Farid NR J Endocrinol Invest; 2001; 24(7):536-45. PubMed ID: 11508790 [TBL] [Abstract][Full Text] [Related]
2. Thyroid carcinoma is characterized by genomic instability: evidence from p53 mutations. Shahedian B; Shi Y; Zou M; Farid NR Mol Genet Metab; 2001 Feb; 72(2):155-63. PubMed ID: 11161841 [TBL] [Abstract][Full Text] [Related]
3. p53 gene mutations associated with anaplastic transformation of human thyroid carcinomas. Nakamura T; Yana I; Kobayashi T; Shin E; Karakawa K; Fujita S; Miya A; Mori T; Nishisho I; Takai S Jpn J Cancer Res; 1992 Dec; 83(12):1293-8. PubMed ID: 1483945 [TBL] [Abstract][Full Text] [Related]
4. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. Fagin JA; Matsuo K; Karmakar A; Chen DL; Tang SH; Koeffler HP J Clin Invest; 1993 Jan; 91(1):179-84. PubMed ID: 8423216 [TBL] [Abstract][Full Text] [Related]
5. p53 mutations in all stages of thyroid carcinomas. Zou M; Shi Y; Farid NR J Clin Endocrinol Metab; 1993 Oct; 77(4):1054-8. PubMed ID: 8408453 [TBL] [Abstract][Full Text] [Related]
6. p53 tumor suppressor gene status and the degree of genomic instability in sporadic colorectal cancers. Kahlenberg MS; Stoler DL; Basik M; Petrelli NJ; Rodriguez-Bigas M; Anderson GR J Natl Cancer Inst; 1996 Nov; 88(22):1665-70. PubMed ID: 8931611 [TBL] [Abstract][Full Text] [Related]
7. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. Donghi R; Longoni A; Pilotti S; Michieli P; Della Porta G; Pierotti MA J Clin Invest; 1993 Apr; 91(4):1753-60. PubMed ID: 8473515 [TBL] [Abstract][Full Text] [Related]
8. Prevalence of mutations of ras and p53 in benign and malignant thyroid tumors from children exposed to radiation after the Chernobyl nuclear accident. Nikiforov YE; Nikiforova MN; Gnepp DR; Fagin JA Oncogene; 1996 Aug; 13(4):687-93. PubMed ID: 8761289 [TBL] [Abstract][Full Text] [Related]
9. Immunocytochemical detection of p53 in human thyroid carcinomas is associated with mutation and immortalization of cell lines. Jossart GH; Epstein HD; Shaver JK; Weier HU; Greulich KM; Tezelman S; Grossman RF; Siperstein AE; Duh QY; Clark OH J Clin Endocrinol Metab; 1996 Oct; 81(10):3498-504. PubMed ID: 8855792 [TBL] [Abstract][Full Text] [Related]
10. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Ito T; Seyama T; Mizuno T; Tsuyama N; Hayashi T; Hayashi Y; Dohi K; Nakamura N; Akiyama M Cancer Res; 1992 Mar; 52(5):1369-71. PubMed ID: 1737400 [TBL] [Abstract][Full Text] [Related]
11. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer. Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332 [TBL] [Abstract][Full Text] [Related]
12. [Unique association of p53 mutations with undifferentiated carcinoma of the thyroid]. Ito T; Seyama T; Hayashi Y; Dohi K; Akiyama M Nihon Rinsho; 1994 Apr; 52(4):1069-74. PubMed ID: 8196165 [TBL] [Abstract][Full Text] [Related]
14. Molecular genetic alterations of FHIT and p53 genes in benign and malignant thyroid gland lesions. Pavelić K; Dedivitis RA; Kapitanović S; Cacev T; Guirado CR; Danić D; Radosević S; Brkić K; Pegan B; Krizanac S; Kusić Z; Spaventi S; Bura M Mutat Res; 2006 Jul; 599(1-2):45-57. PubMed ID: 16698048 [TBL] [Abstract][Full Text] [Related]
15. Silent and multiple mutations in p53 and the question of the hypermutability of tumors. Strauss BS Carcinogenesis; 1997 Aug; 18(8):1445-52. PubMed ID: 9276614 [TBL] [Abstract][Full Text] [Related]
16. Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma. Hermann S; Sturm I; Mrozek A; Klosterhalfen B; Hauptmann S; Dörken B; Daniel PT Int J Cancer; 2001 Jun; 92(6):805-11. PubMed ID: 11351299 [TBL] [Abstract][Full Text] [Related]
17. Significance of P53 in human thyroid tumors. Simon D; Goretzki PE; Gorelev V; Ebling B; Reishaus E; Lyons J; Haubruck H; Röher HD World J Surg; 1994; 18(4):535-40; discussion 540-1. PubMed ID: 7725741 [TBL] [Abstract][Full Text] [Related]
18. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan. Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413 [TBL] [Abstract][Full Text] [Related]
19. Promoter hypermethylation of the DNA repair gene O(6)-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. Esteller M; Risques RA; Toyota M; Capella G; Moreno V; Peinado MA; Baylin SB; Herman JG Cancer Res; 2001 Jun; 61(12):4689-92. PubMed ID: 11406538 [TBL] [Abstract][Full Text] [Related]
20. Mutation of the p53 gene in a differentiated human thyroid carcinoma cell line, but not in primary thyroid tumours. Wright PA; Lemoine NR; Goretzki PE; Wyllie FS; Bond J; Hughes C; Röher HD; Williams ED; Wynford-Thomas D Oncogene; 1991 Sep; 6(9):1693-7. PubMed ID: 1923534 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]